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Background
Profiling the gene expression of solid tumors can assist in
predicting patients’ responses to immunotherapy.
However, extracting gene expression traditionally
requires invasive biopsies or surgeries, which is
impracticable for late-stage patients with multiple lesions.
Additionally, biopsies are time-consuming, expensive,
and invasive nature, they are usually taken only once
before treatment. However, gene expression is expected
to change in response to treatment, and this longitudinal
information could improve physicians’ decision making.1
Novel techniques for monitoring gene expression in solid
tumors have the potential to improve personalized cancer
treatment.
Radiogenomics is an emerging field that principally aims
to correlate features from imaging to gene expression.2 In
this way, it is non-invasive and easily integrates into the
current clinical workflow. However, progress into
Motivation
Patients with late-stage non-small cell lung cancer
(NSCLC) often cannot get a biopsy at every lesion.
Moreover, most NSCLC patients worldwide lack access
to gene expression testing, but can receive CT scans.
Therefore, we sought to develop a model capable of
predicting gene expression exclusively from CT scans of
each lesion. Such a model could improve choice of
treatment for late-stage patients, could provide a
longitudinal view of gene expression, and would serve as
a proof-of-concept for future radiogenomic models.
As shown in Figure 1, the overall approach relies on both unsupervised
and supervised machine learning. First, unsupervised learning is used to
cluster patients with similar immune profiles. Then, supervised machine
learning is performed to predict clusters from the imaging features.
Before performing the unsupervised clustering, first the genomic data
needed to be processed. Genomic data and pre-treatment CT scans
were identified from multiple institutions for 274 patients with early-stage
NSCLC.3 Gene expression data was log2 normalized across each
cohort, and then each pathway of each cohort was normalized using Z-
Score normalizing. This approach assumed that the distribution of gene
expression were identical in each cohort but was necessary in order to
normalize between cohorts. Then, using gene set enrichment analysis,
the normalized gene expression was converted into common pathways
associated with immune response. The patients were then clustered
using a variety of algorithms, including partition around medoid (PAM), k-
means, hierarchical clustering, and spectral clustering. Ultimately,
consensus clustering with the k-means algorithm using Euclidean
distance was found to provide the most robust and distinct clusters. The
heatmap of immune pathways, and the clusters, is shown in Figure 2.
Fig 2. Heatmap of the genetic pathways, clustered by patient. The
colored bars at the top denote each of the different clusters. Red
indicates larger values, and blue indicates smaller. From left to right,
the clusters were interpreted as immune “neutral,” “cold,” and ”hot”.
The labels on the right list the immune pathways, and the rows
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Fig 1. Overview of the proposed approach using
unsupervised learning to find immune activity
clusters, and the corresponding radiomics pipeline to
classify clusters from imaging.
Each lesion was segmented by an experienced radiologist, after which
they were processed through the conventional and deep learning
pipelines. Conventional radiomics features were extracted using the
pyradiomics package,4 an in-house program to extract regional variation,
and an in-house program that describes the tumor structure using
spherical harmonics. Deep learning features will be extracted using an
3D autoencoder to compress the tumor into a low-dimension latent
space that provides rich tumor features. Ultimately, 412 conventional
radiomic features were found.
Model Accuracy Precision Recall F1 AUC_ROC
Logistic 
Regression




0.54 0.27 0.50 0.38 0.47
Random 
Forest
0.53 0.52 0.52 0.52 0.53
Table 1. Results of various machine learning models in
attempting to classify immune hot or immune cold from the
imaging features. The top results are bolded.
Fig 3. a)Box plots of the feature with the highest differences
between classes. The classes are immune ”neutral”, “cold,” and
“hot” from left to right. p=0.08 b) Confusion Matrix of a Random
Forest model trained to predict three classes.
Results
The heatmap in Figure 2 demonstrates that 3 clear
classes were found. Three classes were found in most
clustering methods; however, many samples were
clustered differently depending on the algorithm used.
While the genomic results yielded distinct clusters, it was
much harder to correlate the radiomic features to the gene
expression. Figure 3 shows the box plots of the feature
with the most interclass variation. The large amount of
overlap suggests that the features do not strongly
correlate to the different gene clusters.
The lack of correlation between the conventional radiomic
features and the gene expression clusters was confirmed
by the results of the ML models, shown in table 1. Since
these models are scarcely predicting better than a random
guess, either better features or better models must be
developed in order to develop a robust radiogenomics
model.
Conclusion
This study aimed to build a radiogenomic model in order to
predict whether a patient would respond to
immunotherapy. No meaningful correlation was found
between the radiomic features and the gene expression
clusters; however, the study is currently not complete.
Notably, deep learning features have not yet been
extracted from the CT scans, and they have significantly
more potential to enable an accurate radiogenomic model.
After the model is built, it will be validated by applying it to
a cohort of 182 patients with late-stage NSCLC from the
LONESTAR clinical trial that do not have gene expression
data, and hopefully showing that the predicted clusters
predict changes in tumor volume.
Univariate testing correlated each radiomic feature with
the gene expression clusters. Additionally, machine
learning (ML) models, including Support Vector Machine
(SVM), and Random Forest (RF) was used to predict the
gene expression cluster from the radiomic features.
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